China-based molecular diagnostic reagent specialist Shanghai Liferiver Bio-Tech Co., Ltd (SHA: 688317) has announced receiving Category III medical device license from the National Medical Products Administration (NMPA) for its hepatitis C virus (HCV) nucleic acid test kit (fluorescent PCR method). This product is designed for the quantitative detection of HCV RNA in human serum and plasma samples.
Advanced Detection Technology
The kit employs a high-sensitivity hepatitis C nucleic acid detection scheme with a sensitivity of 15IU/mL. This innovative approach significantly enhances detection sensitivity compared to conventional reagents, shortens the detection window period, and enables precise control of the critical time for diagnosis and treatment of HCV-infected individuals.-Fineline Info & Tech
